breast cancer

Barclay, N. L., Català, M., Jödicke, A. M., Prieto-Alhambra, D., Newby, D., Delmestri, A., et al. (2024). Collateral effects of the COVID-19 pandemic on endocrine treatments for breast and prostate cancer in the UK: a cohort study. Ther Adv Med Oncol, 16, 17588359241253115. http://doi.org/10.1177/17588359241253115

View

Hagberg, K. W., Vasilakis-Scaramozza, C., Persson, R., Neasham, D., Kafatos, G., & Jick, S. (2023). Correctness and Completeness of Breast Cancer Diagnoses Recorded in UK CPRD Aurum and CPRD GOLD Databases: Comparison to Hospital Episode Statistics and Cancer Registry (Companion Paper 2). Clin Epidemiol, 15, 1193-1206. http://doi.org/10.2147/clep.s434829

View

Hagberg, K. W., Vasilakis-Scaramozza, C., Persson, R., Neasham, D., Kafatos, G., & Jick, S. (2023). Presence of Breast Cancer Information Recorded in United Kingdom Primary Care Databases: Comparison of CPRD Aurum and CPRD GOLD (Companion Paper 1). Clin Epidemiol, 15, 1183-1192. http://doi.org/10.2147/clep.s434795

View

Khosrow-Khavar, F., Azoulay, L., Montastruc, J. L., Montastruc, F., & Renoux, C. (2022). Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study. Cancer. http://doi.org/10.1002/cncr.34208

View

Bromley, S. E., Matthews, A., Smeeth, L., Stanway, S., & Bhaskaran, K. (2019). Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK. J Cancer Surviv. http://doi.org/10.1007/s11764-019-00782-w

View